Wanhong Zhao

Wanhong Zhao

Auto-generated profile, based on publicly available information

Wanhong Zhao

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JMJian-Qing Mi
Jian-Qing Mi
WZWanhong Zhao
Wanhong Zhao
HJHongmei Jing
Hongmei Jing
WFWeijun Fu
Weijun Fu
JHJianda Hu
Jianda Hu
SCSai-Juan Chen
Sai-Juan Chen
PURPOSE: CARTIFAN-1 aimed to evaluate the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–targeting chimeric antigen receptor T-cell therapy, in Chinese patients with relapsed/refractory multiple myeloma (RRMM). METHODS: This pivotal phase II, open-label study (ClinicalTrials.gov identifier: NCT03758417 ), conducted across eight sites in China, enrolled adult patients with RRMM who had received ≥ 3 lines of prior therapy, including a proteasome inhibitor and immunomodulatory drug. Patients received a single infusion of cilta-cel (target dose 0.75 × 106 chimeric antigen receptor–positive viable T cells/kg). The primary end point was overall response rate. Secondary end points included progression-free survival (PFS), overall survival (OS), and incidence and severity of adverse events (AEs). RESULTS: As of the clinical cutoff of July 19, 2021, 48 patients received a cilta-cel infusion. At an 18-month median follow-up, the overall response rate was 89.6% (95% CI, 77.3 to 96.5), with a median time to first response of approximately 1 month; 77.1% of patients (95% CI, 62.7 to 88.0) achieved complete response or better. Medians for duration of response, PFS, and OS were not reached. The 18-month PFS and OS rates were 66.8% (95% CI, 49.4 to 79.4) and 78.7% (95% CI, 64.0 to 88.0), respectively. Hematologic AEs were common, including anemia (100%), neutropenia (97.9%), lymphopenia (95.8%), and thrombocytopenia (87.5%). Cytokine release syndrome occurred in 97.9% of patients (35.4% grade 3/4); the median time to onset was 7 days, and the median duration was 5 days. Infections occurred in 85.4% of patients (37.5% grade 3/4). Ten deaths occurred after cilta-cel infusion, eight of which were due to treatment-related AEs. CONCLUSION: These data demonstrate a favorable risk-benefit profile for a single infusion of cilta-cel, resulting in early, deep, and durable responses in heavily pretreated patients with RRMM in China.

1 March 2017 in Immunology Letters
Verified
Journal Article
Closed access
WZWanhong Zhao
Wanhong Zhao
YZYi-Lin Zhang
Yi-Lin Zhang
PZPengyu Zhang
Pengyu Zhang
JYJuan Yang
Juan Yang
LZLongjin Zhang
Longjin Zhang
Hideto TamuraHideto Tamura
Hideto Tamura

1 August 2003 in The Thoracic and Cardiovascular Surgeon
Verified
Journal Article
Closed access
PDF file
ZWZ. P. Wang
Z. P. Wang
CYChen Yang
Chen Yang
LHL. B. Huang
L. B. Huang
WZW. Zhao
W. Zhao
WHW. M. Huang
W. M. Huang
A 12-year-old girl complained of tachycardia and dyspnea after exertion but without cyanosis. Her echocardiogram showed an ASD and a widened inferior vena cava. A difference in PO2 between inferior and superior vena cava was evident. An anastomosis between left atrium and pulmonary vein, and a long oval pericardium to cover the opening of the descending vein and ASD into left atrium were performed during cardiopulmonary bypass. The patient recovered without complications.

23 May 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
JMJian-Qing Mi
Jian-Qing Mi
WZWanhong Zhao
Wanhong Zhao
HJHongmei Jing
Hongmei Jing
JJJie Jin
Jie Jin
SCSai-Juan Chen
Sai-Juan Chen